Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Abstract

With the recent success of adenoviral vaccines against Ebola and SARS-CoV-2, the potential of this platform in the fight against outbreak pathogens is being realized for human infectious diseases. This technology is suitable for large scale manufacture and relatively low cost. The potential of viral-vectors to induce T Helper type 1 and high antibody responses makes the use of this approach attractive in efforts to combat the disease and disability caused by viral pathogens. However, the case for their use in bacterial vaccines is less clear: the expression of a bacterial protein in a eukaryotic cell may impact on the antigen localization, induce unwanted glycosylation or affect protein conformation, and this is also true if using the mRNA vaccine platform. The potential and challenges of adenoviral vectors was explored against two bacterial diseases. While our work highlights the challenges inherent in developing novel vaccines using this technology and can be applied to mRNA, the successful progression of two novel bacterial vaccines to clinical development underlines the potential of these platforms for vaccine development against bacterial diseases, and their potential for veterinary use.

University members only.

Forthcoming events

Will the next pandemic be caused by H5N1 influenza?

Monday, 02 June 2025, 1pm to 2pm @ Richard Doll Lecture Theatre

The world is currently experiencing a panzootic of H5N1 influenza. Wild birds have carried the virus across all continents and an unprecedented number of mammalian species have been infected including humans. What will it take for this virus to go pandemic, and does the introduction of the virus into dairy herds in USA bring that one step closer? Wendy will discuss the current knowledge on host range barriers that protect us from more frequent zoonoses and pandemic from bird flu, and show how we can use this scientific knowledge to risk assess the current situation.

Better treatment for tuberculosis

Monday, 09 June 2025, 1pm to 2pm @ BDI/OxPop Building LG seminar rooms

Resolving the genetic basis of type 2 diabetes in 125 000 Mexicans

Tuesday, 10 June 2025, 1pm to 2pm @ Richard Doll Lecture Theatre

The burden of drug resistant infections, the GRAM project

Monday, 16 June 2025, 1pm to 2pm @ BDI/OxPop Building LG seminar rooms

Large scale genetic consortia

Tuesday, 17 June 2025, 1pm to 2pm @ Richard Doll lecture theatre